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Abstract
Background: Lupus erythematosus (LE) is a heterogeneous disease ranging from mainly skin-restricted manifestations
(discoid LE [DLE] and subacute cutaneous LE) to a progressive multisystem disease (systemic LE [SLE]). Genetic association
studies have recently identified several strong susceptibility genes for SLE, including integrin alpha M (ITGAM), also known
as CD11b, whereas the genetic background of DLE is less clear.
Principal Findings: To specifically investigate whether ITGAM is a susceptibility gene not only for SLE, but also for cutaneous
DLE, we genotyped 177 patients with DLE, 85 patients with sporadic SLE, 190 index cases from SLE families and 395
population control individuals from Finland for nine genetic markers at the ITGAM locus. SLE patients were further
subdivided by the presence or absence of discoid rash and renal involvement. In addition, 235 Finnish and Swedish patients
positive for Ro/SSA-autoantibodies were included in a subphenotype analysis. Analysis of the ITGAM coding variant
rs1143679 showed highly significant association to DLE in patients without signs of systemic disease (P-value =4.73610
211,
OR =3.20, 95% CI =2.23–4.57). Significant association was also detected to SLE patients (P-value =8.29610
26, OR =2.14,
95% CI =1.52–3.00), and even stronger association was found when stratifying SLE patients by presence of discoid rash (P-
value =3.59610
28, OR =3.76, 95% CI =2.29–6.18).
Significance: We propose ITGAM as a novel susceptibility gene for cutaneous DLE. The risk effect is independent of systemic
involvement and has an even stronger genetic influence on the risk of DLE than of SLE.
Citation: Ja ¨rvinen TM, Hellquist A, Koskenmies S, Einarsdottir E, Panelius J, et al. (2010) Polymorphisms of the ITGAM Gene Confer Higher Risk of Discoid
Cutaneous Than of Systemic Lupus Erythematosus. PLoS ONE 5(12): e14212. doi:10.1371/journal.pone.0014212
Editor: Benjamin Edward Rich, Dana-Farber Cancer Institute, United States of America
Received April 26, 2010; Accepted November 10, 2010; Published December 2, 2010
Copyright:  2010 Ja ¨rvinen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by Finska Lakaresallskapet, Academy of Finland, Sigrid Juselius Foundation and Helsinki University Central Hospital Research
Fund (project TYH 2008248), Helsinki Biomedical Graduate School LERU PhD Program in Biomedicine (TMJ), Maire Lisko Foundation (TMJ), Biomedicum Helsinki
Foundation (TMJ), Helsinki University Funds (TMJ), Medical Research Fund of Tampere University Hospital (TH), Finland, Edvard Welander Foundation, Finsen
Foundation, the Swedish Rheumatism Association (FN), the Swedish Foundation for Strategic Research, the Stockholm County Council, Goran Gustafsson
Foundation, Torsten and Ragnar Soderberg Foundation, Heart-Lung Foundation, King Gustaf V Foundation, the Swedish Rheumatism Association (MWH), and the
Swedish Research Council (MWH, USK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: juha.kere@ki.se
{ Deceased
Introduction
Lupus erythematosus (LE) is a complex autoimmune disease
with variable clinical course and manifestations. Cutaneous lupus
erythematosus (CLE) is a heterogeneous disease entity with
manifestations primarily confined to the skin. CLE can be
subdivided into chronic cutaneous lupus erythematosus, of which
discoid lupus erythematosus (DLE) is the most common form,
subacute cutaneous lupus erythematosus (SCLE), and acute
cutaneous lupus erythematosus (ACLE) [1]. ACLE is characteristic
for systemic lupus erythematosus (SLE) that manifests with severe
organ involvement and the presence of haematological and
immunological abnormalities, whereas well demarcated, scarring
plaques of the face, scalp and ears are often seen in DLE patients.
Mild extracutaneous involvement may be present in 14–27% of
patients with DLE [2], while only 5–10% progress to an overt SLE
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e14212[3]. Lesions typical for DLE are seen in 15–20% of SLE patients
[4]. Population-based studies on the prevalence of CLE are rare,
but this condition is estimated to be 2–3 times more frequent than
SLE [5]. Although the pathogenic mechanisms underlying LE are
not yet entirely established, susceptibility is influenced by multiple
genetic and environmental factors, including ultraviolet (UV)
radiation, certain drugs and oestrogen [5].
A complex genetic component similar to that of SLE may also
underlie CLE [3]. The genetic architecture of CLE is poorly
understood, but polymorphisms in HLA genes, the TNF-a pro-
moter and complement molecules have been suggested as strong
candidates for CLE susceptibility [6]. We have recently shown
that the known SLE risk genes TYK2 and IRF5 also associate with
CLE [7].
ITGAM, a member of the immune complex processing pathway,
has been consistently replicated as an SLE susceptibility gene [8–
11]. The coding variant rs1143679 (R77H) was recently shown to
influence the risk of discoid rash in SLE patients [12]. ITGAM
(CD11b, Mac-1) encodes the a-chain of aMb2-integrin (CD11b/
CD18 or CR3), a cell surface receptor for multiple ligands, such as
complement 3 cleavage fragment and intercellular adhesion
molecule-1 (ICAM-1) [13]. The receptor is expressed on
neutrophils, macrophages and dendritic cells and is involved in
leukocyte adhesion, phagocytosis and regulation of apoptosis [13].
The exact disease aggravating mechanism is not known, but
altered interaction with ligands [10] as well as defects in leukocyte
trafficking and uptake of apoptotic cells or immune complexes
have been suggested [14]. As abnormal removal of apoptotic cells
plays an important role in evolving discoid lesions [6], ITGAM is a
plausible candidate gene not only for SLE, but also for cutaneous
DLE.
In the present study, we investigated the role of ITGAM in a
well-characterised cohort of DLE patients without signs of
systemic disease. The disease risk was further compared between
DLE and a cohort of SLE patients that was stratified for various
clinical subtypes.
Materials and Methods
Ethics statement
This study was conducted in accordance with the Declaration of
Helsinki Principles. All subjects gave their written informed
consent and the study was approved by the Ethical Review
Boards of Helsinki and Tampere University Central Hospitals,
Finland, and the Regional Human Ethics Committee at the
Karolinska University Hospital, the Institutional Ethics Board and
the Regional Ethics Board, Sweden.
Finnish patients and control individuals
Patients from two Finnish cohorts were included in the present
study. The recruitment of the case-control cohort and its clinical
characteristics have been described recently [15] (Table 1).
Altogether 177 DLE (76% women) and 85 SLE (93% women)
patients with LE-specific skin manifestations [16] diagnosed by a
dermatologist were recruited. The SLE family cohort included 190
probands (94% women) together with their family members (total
n=236) [17]. The diagnosis of DLE was based on generally
accepted clinical, histological and immunofluorescence findings
[1] and exclusion of SCLE or SLE. In DLE patients without the
characteristic discoid rash (n=14/177 patients) the diagnosis was
based on other phenotype-specific manifestations, such as absence
of antinuclear and/or double-stranded DNA antibodies, no signs
of extracutaneous disease and dermal perifollicular or perivascu-
lar mononuclear cell infiltrate [1] as well as careful clinical
examination of patients and patient chart review. Furthermore,
the histology and location of lesions usually in the head region, the
absence of systemic manifestations and negative laboratory
findings in these 14 cases supported the diagnosis of DLE rather
than SCLE or SLE. All SLE patients fulfilled the revised 1982
ACR classification criteria by Tan et al. [18] for SLE as confirmed
by a rheumatologist. A total of 356 anonymous Finnish controls
(49% women) comprising of unaffected spouses or common-law
spouses of patients and a collection of unrelated healthy
individuals were included in the study.
Swedish patients and control individuals
PatientsfromtwoseparateSwedishcohortswerealsoutilisedinthe
present study. Swedish patients (n=91) participating in a study
assessing the incidence and prevalence of SCLE in Stockholm in
1996–2002 [19] (Table 2) were included. In brief, patients positive for
Ro/SSA-autoantibodies (Ro-positive patients without signs of
systemic inflammation =21, DLE =2, SCLE =8, SLE =31,
Sjo ¨gren’s syndrome [SS] =23, undifferentiated connective tissue
disease [UCTD] =6) reported their occurrence of photosensitivity
and skin symptoms in a questionnaire. Patients were examined
clinically (KP and FN) at the Department of Dermatology, Danderyd
Hospital,Stockholm,Sweden.Clinicaldatawerecompletedbasedon
patient history and medical records. The diagnoses of DLE and
SCLE were based on the clinical and histopathological features [1].
The diagnoses of SLE and SS were based on the revised 1982 ACR
[18] and the revised European criteria [20], respectively. A diagnosis
Table 1. Clinical and demographic characteristics of the sets
of Finnish patient samples in this study.
Finnish case-control sample
DLE
(n=177)
SLE
(n=85)
SLE families
(n=236
patients)
Female 76 93 94
Mean age at onset (range; yrs) 42 (15–77) 36 (8–85) 29 (1–66)
Mean age at diagnosis (range; yrs) 45 (17–77) 40 (13–86) 33 (6–72)
Butterfly rash 11 72 51
Discoid rash 92 44 10
Annular SCLE lesions 1 12 na
Psoriasiform SCLE lesions 1 22 na
Photosensitivity 65 80 69
Mouth ulcers 4 18 18
Arthritis 2 64 83
Renal involvement 1 20 30
Leukopenia 7 37 68
Thrombocytopenia 5 17 16
Elevated antinuclear antibodies 28 98 na
Ro/SSA-antibody positivity
1 25 66 na
La/SSB-antibody positivity
1 43 1 n a
Double-stranded DNA antibody
positivity
93 7 n a
1Because of differences in laboratory methods and reference values, only
patients from Helsinki were included.
Na = not available.
Percentage (%) of patients with each phenotype is shown except for mean age,
which is shown in years (yrs).
doi:10.1371/journal.pone.0014212.t001
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connective tissue disease and the presence of antinuclear antibodies at
two different occasions [21]. Ro-autoantibodies were tested in
accredited laboratories in Stockholm using enzyme-linked immuno-
sorbent assay (ELISA) [19].
Another Swedish cohort consisted of patients with SS (n=73)
fulfilling the revised European criteria [20] and attending the
Karolinska University Hospital, Stockholm, Sweden during 1998–
2008 (Table 2). The diagnosis was verified by a combination of
clinical examination by rheumatologists or medical doctors and a
questionnaire. Ro/SSA-autoantibodies were detected by an
ELISA using recombinant, purified Ro52 and Ro60 antigens [22].
A total of 164 Swedish patients with a diagnosis of a connective
tissue disease from two distinct cohorts were thus included in the
study. Out of these 164 genotyped patients, altogether 134 indi-
viduals were positive for Ro/SSA-autoantibodies and were further
utilised to evaluate the role of ITGAM in the presence of Ro
response. Swedish control samples (n=295; 90.5% women) were
population-based anonymous control individuals from the Epide-
miological Investigation of Rheumatoid Arthritis (EIRA) study [23].
Genotyping
After review of the literature regarding ITGAM published prior
to the initiation of this study [8–10], eleven single nucleotide
polymorphisms (SNP) at the ITGAM locus showing replicated
association to SLE in different populations were selected for
genotyping: rs1143679, rs9936831, rs9937837, rs9888879,
rs12928810, rs9888739, rs11860650, rs6565227, rs1143678,
rs4548893 and rs11574637.
Genotyping was performed according to manufacturer’s
instructions using Sequenom iPLEX Gold chemistry [24]
(Sequenom Inc., San Diego, California, USA). Assay design and
genotyping were performed in the genotyping core facility at
Karolinska Institutet, Huddinge, Sweden. The average genotyping
success rate of each marker was 94% for the Finnish case-control
cohort, 96% for the Finnish SLE families and 94% for the Swedish
case-control cohort; all markers were in Hardy-Weinberg equili-
brium (P.0.05) in controls. The markers rs12928810 (only in SLE
families), rs6565227 and rs1143678 had success rates below our
threshold (,85%) and were thus excluded.
Statistical analysis
Haploview v. 4.0 [25] was used to study linkage disequilibrium
(LD) patterns, estimate haplotypes (Figure 1A–C) and perform
association analyses. To increase the statistical power of the
association analysis, the sporadic SLE cases (n=85) were analysed
in combination with unrelated probands (n=190) from the SLE
family cohort, thus giving a total of 275 independent Finnish SLE
patients and 356 controls for analysis. Allele and haplotype counts
were compared between patients and controls by chi-square test,
and permutation testing (10 000 iterations) as implemented into
Haploview was performed in order to obtain a measure of
significance corrected for multiple testing bias. Due the strong LD
(Figure 1A) throughout the ITGAM locus and thus dependence
between markers, traditional Bonferroni correction would likely to
be overly conservative. Two-tailed, uncorrected P-values are
reported in the Results section, and odds ratios (OR) with their
respective 95% confidence intervals (CI) were calculated using
GraphPad Prism v.4.03 (GraphPad Software Inc., La Jolla, CA,
USA).
Patient stratification for subphenotype analysis
Finnish SLE patients were further stratified by presence of
discoid rash (n=55) and renal involvement (n=76) defined as
fulfilment of the ACR renal criteria [18]. Finnish (n=101) and
Swedish (n=134) patients positive for Ro/SSA-autoantibodies
were first analysed individually and further in combination
(n=235) as a pooled dataset in order to study the association
between ITGAM and immunological factors [12,26]. Ro-autoan-
tibodies were selected for detailed investigation, because they may
have pathobiological importance in apoptosis and phagocytosis
[27] similarly to ITGAM, and prognostic value for predicting
systemic inflammatory disease [28]. Furthermore, several genetic
regions harbouring genes for adhesion molecules have shown
evidence of association to DLE in the presence of Ro-
autoantibodies [6] and the disease progression may be highly
dynamic in Ro-positive patients [29].
Power calculations
The power to detect association of ITGAM to different forms of
LE in our sample sets was estimated using the online Power for
Association With Error program (http://linkage.rockefeller.edu/
pawe/). We assumed a risk allele frequency of 0.185, an OR of
1.70 [11] and alpha 0.05. The average power to detect association
of ITGAM polymorphisms was 84% in DLE and 91% in SLE. In
subphenotype analyses when using reported reference values [12],
the power to detect association of rs1143679 was 77% in SLE
with discoid rash and 92% in SLE with renal involvement. For
Table 2. Clinical and demographic characteristics of the
Swedish sample sets in this study.
Swedish case-control sample
Connective tissue
disease patients
(n=91)
1
Sjo ¨gren’s
syndrome patients
(n=73)
2
Female 91 95
Mean age at onset (range; yrs) 58 (18–83)
3 na
Mean age at diagnosis
(range; yrs)
na 52 (20–87)
Butterfly rash 13 na
Discoid rash 19 na
Annular SCLE lesions 14 na
Psoriasiform SCLE lesions 0 na
Photosensitivity 100 na
Mouth ulcers na na
Arthritis 5 23
Renal involvement 5 4
Leukopenia na 18
Thrombocytopenia na 3
Elevated antinuclear antibodies 74 55
Ro/SSA antibody positivity 100 59
La/SSB antibody positivity 38 38
Double-stranded DNA antibody
positivity
13 na
1Ro/SSA positive patients without signs of systemic inflammation =21, DLE =2,
SCLE =8, SLE =31, SS =23, UCTD =6 from the study of Popovic et al. [19].
2SS patients, data provided by Prof. Marie Wahren-Herlenius, MD, PhD, Dept. of
Medicine, Rheumatology Unit, Karolinska Institutet, Solna, Sweden.
3Mean age at initial testing for Ro/SSA-autoantibodies [19].
Na = data not available.
Percentage (%) of patients is shown except for mean age, which is shown in
years (yrs).
doi:10.1371/journal.pone.0014212.t002
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70%, 75% and 95%, respectively, was obtained when previously
reported risk estimates were assumed [11].
Results
Nine ITGAM SNPs were successfully genotyped in three datasets
corresponding to two different LE subgroups (Finnish patients with
DLE or SLE) and control individuals. Subphenotype analyses were
further performed to investigate the role of ITGAM in specific
clinical manifestations. These analyses showed that the magnitude
of association was strongest in cutaneous DLE (P-value
$3.7610
211; uncorrected P-values are reported), followed by
SLE patients with discoid rash (P-value $3.9610
29) and all SLE
patients together (P-value $8.2610
26) (Table 3). The associations
were more modest in SLE patients with renal involvement (P-value
$5.8610
25) (Table 4), in Finnish (P-value $6.3610
26)a n d
Swedish (P-value $0.01) Ro/SSA-positive patients as well as in
the pooled dataset positive for Ro-antibodies (P-value $6.4610
26)
(Table 5). As hypothesised, the marker rs1143679 (R77H) showed
the strongest association in DLE, SLE and SLE with discoid rash
(P-value range from 4.7610
211 to 8.3610
26) (Table 3). The same
marker was observed to reach a more humble, although statistically
significant, effect in subphenotype analyses (P-value range from
6.4610
26 to 0.04) (Tables 4 and 5),which may mirror the impact of
sample size. In addition to rs1143679, the eight other markers
studied were observed to associate significantly in Finnish patients
(Tables 3, 4, 5), whereas Swedish patients showed borderline
association (Table 5). In general, the risk allele frequencies were
somewhat higher in DLE, and SLE patients with discoid rash
compared to unstratified SLE patients in our study (Table 3) or
previous studies, whereas our control individuals had frequencies
similar to other control populations of European origin [8,10,11]. A
similar increase in ORs was also observed, the risk estimates being
highest in SLE patients with discoid rash (range 2.46–3.95) and in
DLE patients (range 1.65–3.20) followed by unstratified SLE
patients (range 1.52–2.14) (Table 3), SLE patients with renal
involvement (range 1.82–2.53) (Table 4) and Ro-positive patients
(range 1.37–2.03 in the pooled dataset) (Table 5).
Haplotype associations
The haplotype structure of ITGAM was further investigated in
each set of samples, but this neither improved statistical significance
nor yielded any further information (Figure 1 B). One high risk
Figure 1. Linkage disequilibrium (LD) patterns across the ITGAM-ITGAX locus and haplotype association analysis results. A) LD plot of
the genotyped ITGAM region on chromosome 16p11 (HapMap CEU data from build 36). Darker colour denotes higher LD (D’). Asterisks indicate single
nucleotide polymorphism (SNP) markers genotyped in all datasets in the study. B) Haplotype associations for markers conferring risk for cutaneous
DLE, SLE with discoid rash and unstratified SLE. Haplotype 2 is associated with increased, and haplotypes 1 and 3 with decreased risk of cutaneous
DLE, SLE with discoid rash, and SLE. Haplotype 2 carries the minor allele A (in bold) of rs1143679, shown in previous studies to tag risk haplotypes for
SLE. Significant P-values are indicated in bold. The order of SNPs in haplotypes is as follows: rs1143679 - rs9936831 - rs9937837 - rs9888879 -
rs12928810 - rs9888739 - rs11860650 - rs4548893 - rs11574637. C) LD plot of the genotyped SNPs in the DLE dataset. Similar LD patterns were
observed in unstratified SLE and in SLE patients stratified for discoid rash and renal involvement as well as in Ro/SSA-positive patients (data not
shown).
doi:10.1371/journal.pone.0014212.g001
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CATTTC; P-value =7.4610
212, OR =3.33, 95% CI =2.33–
4.75) and two haplotypes with a protective effect (GATTGCCCT;
P-value =7.6610
25, OR =0.58, 95% CI =0.44–0.76, and
GAGTGCCCT; P-value =1.7610
22, OR =0.57, 95% CI
=0.36–0.92), reaching statistical significance, were found in DLE
(Figure 1B). The same risk haplotype with equally strong effect on
risk was observed in SLE (OR =2.20, 95% CI =1.57–3.09), in
SLE patients with discoid rash (OR =4.03, 95% CI =2.47–6.59)
(Figure 1B)and inSLEpatientswith renalinvolvement(OR =2.59,
95% CI =1.60–4.21) (data not shown). Finnish and Swedish
patients positive for Ro/SSA-autoantibodies analysed either
separately or pooled together showed the same haplotype patterns
as DLE and SLE patients (data not shown). In line with other
studied patient groups, the risk conferring ATGCATTTC haplo-
type showed evidence of strong association (P=3.0610
26,O R
=2.08, 95% CI =1.52–2.83) within Ro-positive patients when
Finnish and Swedish subjects were analysed in combination.
Table 3. Single marker association results in Finnish DLE, in SLE with discoid rash and in SLE patients.
Marker Alleles
Associated
allele
Controls
(n=356) DLE (n=177) SLE with discoid rash (n=55) SLE (n=275)
Freq. Freq.
P-value
(corrected)
OR
(95% CI) Freq.
P-value
(corrected)
OR
(95% CI) Freq.
P-value
(corrected)
OR
(95% CI)
rs1143679 A/G A 0.10 0.26 4.73610
211
(,0.0001)
3.20
(2.23–4.57)
0.29 3.59610
28
(,0.0001)
3.76
(2.29–6.18)
0.19 8.29610
26
(,0.0001)
2.14
(1.52–3.00)
rs9936831 T/A T 0.10 0.26 2.14610
210
(,0.0001)
3.03
(2.13–4.31)
0.31 3.99610
29
(,0.0001)
3.95
(2.44–6.40)
0.19 1.32610
25
(,0.0001)
2.08
(1.49–2.90)
rs9937837 G/T G 0.24 0.34 6.00610
24
(0.004)
1.65
(1.24–2.20)
0.43 1.97610
25
(5.00610
24)
2.46
(1.61–3.76)
0.32 1.20610
23
(0.01)
1.52
(1.18–1.96)
rs9888879 C/T C 0.10 0.26 7.57610
211
(,0.0001)
3.06
(2.16–4.34)
0.31 3.38610
29
(,0.0001)
3.93
(2.43–6.34)
0.19 1.10610
25
(,0.0001)
2.06
(1.49–2.86)
rs12928810 A/G A 0.10 0.23 8.03610
28
(,0.0001)
2.77
(1.89–4.07)
na
1 na na na
1 na na
rs9888739 T/C T 0.10 0.25 2.91610
210
(,0.0001)
3.01
(2.12–4.29)
0.30 1.03610
28
(,0.0001)
3.88
(2.38–6.33)
0.18 7.52610
25
(7.00610
24)
1.96
(1.40–2.74)
rs11860650 T/C T 0.10 0.27 3.71610
211
(,0.0001)
3.13
(2.21–4.43)
0.31 1.10610
28
(,0.0001)
3.81
(2.35–6.18)
0.19 3.36610
25
(1.00610
24)
1.99
(1.43–2.77)
rs4548893 T/C T 0.15 0.32 1.10610
210
(,0.0001)
2.74
(2.00–3.74)
0.35 2.61610
27
(,0.0001)
3.14
(2.00–4.94)
0.22 9.00610
24
(0.008)
1.64
(1.22–2.21)
rs11574637 C/T C 0.15 0.30 2.37610
29
(,0.0001)
2.57
(1.87–3.52)
0.37 1.98610
28
(,0.0001)
3.43
(2.19–5.37)
0.22 5.00610
24
(0.004)
1.69
(1.25–2.27)
The frequency of the associated allele in controls and cases is shown, as well as its uncorrected P-value and P-value corrected for multiple testing (in parentheses) as well
as odds ratio (OR) with 95% confidence interval (CI).
Abbreviations: DLE, discoid lupus erythematosus; SLE, systemic lupus erythematosus.
1The marker has success below the study threshold (,85%) and was excluded from analysis in SLE.
doi:10.1371/journal.pone.0014212.t003
Table 4. Single marker association results in Finnish SLE patients with renal involvement.
Allele associations
Marker Alleles Associated allele Controls (n=356) Patients (n=76)
Freq. Freq. P-value (corrected) OR (95% CI)
rs1143679 A/G A 0.10 0.21 1.00610
24 (0.003) 2.49 (1.54–4.01)
rs9936831 T/A T 0.10 0.22 1.00610
24 (0.003) 2.43 (1.51–3.89)
rs9937837 G/T G 0.24 0.35 0.005 (0.03) 1.74 (1.18–2.57)
rs9888879 C/T C 0.10 0.23 5.83610
25 (0.002) 2.53 (1.59–4.02)
rs9888739 T/C T 0.10 0.20 0.001 (0.01) 2.22 (1.35–3.65)
rs11860650 T/C T 0.10 0.23 9.71610
25 (0.002) 2.49 (1.55–3.97)
rs4548893 T/C T 0.15 0.25 0.002 (0.02) 1.99 (1.29–3.07)
rs11574637 C/T C 0.15 0.24 0.008 (0.05) 1.82 (1.16–2.83)
The frequency of the associated allele in controls and cases is shown, as well as its uncorrected P-value, and P-value corrected for multiple testing (in parentheses) as
well as odds ratio (OR) with 95% confidence interval (CI). The marker rs12928810 has success below the study threshold (,85%) and was excluded from analysis. Renal
involvement is defined as fulfilment of the ACR renal criteria [18].
doi:10.1371/journal.pone.0014212.t004
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In the present study we have shown that polymorphisms at the
ITGAM locus increase the risk of cutaneous DLE three-fold
compared to healthy control individuals, and the magnitude of the
association is five times higher in DLE than in SLE patients. To
our knowledge, the current study is the first to address the role of
ITGAM in a clinically verified cohort of cutaneous DLE patients
without signs of systemic disease. We furthermore replicated in our
series of SLE patients the recent observation of Kim-Howard et al.
[12] that the coding variant rs1143679 (R77H) may influence the
risk of discoid rash in SLE.
The marker rs1143679 showed strong association inDLE,in SLE
patients with discoid rash and in all SLE patients together. In patient
subgroups stratified for renal involvement or Ro/SSA-autoantibody
positivity more modest association was observed. The ITGAM exon
3 variant rs1143679 was originally identified and replicated in three
different populations [10] parallel with GWA studies [8,9]. To date,
its robust association with SLE has been confirmed in a meta-
analysis encompassing populations across the world [11], but it has
not previously been studied in the cutaneous forms of LE.
Several variants within ITGAM and the adjacent ITGAX gene
(Table 3) were found to associate strongly to DLE and also to SLE
with discoid rash. It has, however, been speculated that thesemultiple
association signals are mainly reflecting the strong LD between
rs1143679 and nearby markers [11] (Figure 1A), as any haplotype
carrying the risk allele A at rs1143679 within ITGAM confers risk for
SLE [10]. Our haplotype analysis is in line with this (Figure 1B).
Two previous studies have systematically screened several clinical
subphenotypes of SLE, including patients with renal and immuno-
logical disorders, for association to ITGAM [12,26]. In line with
these reports we observed increased risk in SLE patients with renal
involvement. We further investigated the relationship between
ITGAM and immunological disorders in a group of patients positive
for Ro/SSA-autoantibodies and found significant association in
accordance with findings from a previous study [26]. Possible
pathomechanisms underlying these associations have been pro-
posed [12,26], but not yet established. Interestingly, Ro-autoanti-
bodies and the protein product of the ITGAM gene function on the
same biological pathways of apoptosis and phagocytosis. It has
recently been shown that high Ro52 expression induces apoptosis,
and it has been postulated that apoptotic cell opsonisation with Ro-
positive sera might rather prevent that than facilitate phagocytosis
[27]. However, as Ro-autoantibodies are not exclusive to LE, it is
difficult to draw definitive conclusions about this undoubtedly
complex relationship between ITGAM, Ro-positivity and LE based
on observations by us and others [26].
The only ITGAM variant for which a functional role has been
proposed to date is the previously mentioned rs1143679. This
polymorphism results in an amino acid change (R77H) that may
alter the structure and function of the receptor protein and further
affect its ligand binding activities [10] thus influencing, for
instance, ICAM-1 mediated leukocyte recruitment [10], essential
in the formation of the inflammatory lesions seen in DLE
[6,14,18]. Interestingly, ICAM-1 has been shown to be involved
in the pathogenesis of various types of skin disease [30] especially
in the presence of Ro/SSA-response [3] and it is upregulated in
skin lesions of patients with DLE [30].
ITGAM is also interesting in the context of the photosensitivity
generally observed in DLE patients [6]. UV-B irradiation initiates
a cascade of proinflammatory events in the skin [5,31]. Upon UV
exposure, macrophages expressing ITGAM invade the dermis and
epidermis [32,33], leading to a depletion of antigen presenting
cells [32,34]. There is a delay in dendritic cell differentiation in
UV-exposed skin [34] and antigenic tolerance is induced [31].
Furthermore, IL-10, a cytokine known to trigger DLE, and discoid
rash in SLE [35], is upregulated upon UV exposure. Genetic
alterations of ITGAM function(s) along this pathway may therefore
lead to defects in the suppression of dendritic cell differentiation in
combination with high IL-10 production and induce inadvertent
immune reactions in DLE patients. Furthermore, UV induces also
the production of TNF-a [36], a proinflammatory cytokine that
has been, in combination with pronounced IL-10 production,
suggested to increase DLE risk [35]. Moreover, TNF-a primes
neutrophils to migrate into inflammatory sites through the
upregulation of CD11b/CD18 (aMb2-integrin) [37].
In the present study, a panel of ITGAM polymorphisms was
specifically tested for association to cutaneous DLE in a well-
described cohort of patients that is one of the largest reported. Our
study has contributed with ITGAM to the short list of genes shown
to be associated with DLE. The genetic background of CLE, and
that of DLE in particular, is poorly characterised. Furthermore,
studies on this disease have been difficult to evaluate and replicate
due to low sample sizes non-reporting of risk effect estimates.
There are only a few confirmed risk loci, including HLA genes, the
TNF-a promoter and complement factors [6]. However, TNF-a
shows only modest association [36,38] and the association may be
merely due to the strong LD across the HLA region. These sparse
data indicate that the genetic background of DLE and other forms
of CLE may be very complex and require further studies. Only a
few studies have addressed the gender differences in CLE
pathogenesis [39] and it is still unclear, what the effect of sex in
this disorder may be. Women are known to respond to infection,
vaccination and trauma with increased antibody production and a
more T helper cell 2 predominant immune response, whereas a T
helper cell 1 response and inflammation are usually more severe in
men [40]. Thus, it is reasonable to assume that, especially in the
function of above mentioned immune system related genes, there
would be alterations in the disease mechanisms between female
and male subjects. However, investigating this in future studies is a
challenging task given the female preponderance of the disease,
and carefully matched control individuals are needed as well.
In conclusion, we have demonstrated here a strong novel
association between ITGAM variants and cutaneous DLE without
signs of systemic disease. These variants function independently of
the systemic disease and increase substantially the risk of DLE with
an effect even higher than in SLE. Our results further strengthen
the hypothesis that different forms of LE are not genetically
distinct entities even though their clinical course varies. Based on
its function(s), ITGAM may predispose to DLE through impaired
phagocytosis, leukocyte trafficking or immune suppression in UV-
exposed skin. The exact mechanisms by which ITGAM contributes
to the disease pathogenesis and how its expression may be altered
in affected DLE skin, warrant further studies.
Acknowledgments
This study was completed before the untimely death of Professor Ulpu
Saarialho-Kere (1960–2009) to whose memory this report is dedicated. We
thank Professors Anna-Elina Lehesjoki and Albert de la Chapelle for
providing control samples, Dr. Karin Popovic for clinical investigation and
PhD Valma Harjutsalo for advice in the statistical analysis.
Author Contributions
Conceived and designed the experiments: TMJ. Performed the experi-
ments: AH. Analyzed the data: TMJ. Contributed reagents/materials/
analysis tools: SK EE JP TH HJ LP MK MWH FN JK USK. Wrote the
paper: TMJ SK EE MD USK. Group leader: JK. Project supervision: JK
USK. Critical review of the manuscript: EE MD.
ITGAM in Cutaneous Lupus
PLoS ONE | www.plosone.org 7 December 2010 | Volume 5 | Issue 12 | e14212References
1. Gilliam JN, Sontheimer RD (1981) Distinctive cutaneous subsets in the spectrum
of lupus erythematosus. J Am Acad Dermatol 4: 471–475.
2. Kuhn A, Sontheimer RD (2008) Cutaneous lupus erythematosus: molecular and
cellular basis of clinical findings. Curr Dir Autoimmun 10: 119–140.
3. Lee HJ, Sinha AA (2006) Cutaneous lupus erythematosus: understanding of
clinical features, genetic basis, and pathobiology of disease guides therapeutic
strategies. Autoimmunity 39: 433–444.
4. Yell JA, Mbuagbaw J, Burge SM (1996) Cutaneous manifestations of systemic
lupus erythematosus. Br J Dermatol 135: 355–362.
5. Werth VP (2007) Cutaneous lupus: insights into pathogenesis and disease
classification. Bull NYU Hosp Jt Dis 65: 200–204.
6. Kuhn A, Rondinone R, Doria A, Shoenfeld Y (2005) 1st International
Conference on Cutaneous Lupus Erythematosus Dusseldorf, Germany,
September 1-5, 2004. Autoimmun Rev 4: 66–78.
7. Ja ¨rvinen TM, Hellquist A, Koskenmies S, Einarsdottir E, Koskinen LLE, et al.
(2010) Tyrosine kinase 2 and interferon regulatory factor 5 polymorphisms are
associated with discoid and subacute cutaneous lupus erythematosus. Exp
Dermatol 19: 123–131.
8. Harley JB, Alarcon-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, et al.
(2008) Genome-wide association scan in women with systemic lupus erythema-
tosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other
loci. Nat Genet 40: 204–210.
9. Hom G, Graham RR, Modrek B, Taylor KE, Ortmann W, et al. (2008)
Association of Systemic Lupus Erythematosus with C8orf13-BLK and ITGAM-
ITGAX. N Engl J Med 358: 956–961.
10. Nath SK, Han S, Kim-Howard X, Kelly JA, Viswanathan P, et al. (2008) A
nonsynonymous functional variant in integrin-alpha(M) (encoded by ITGAM) is
associated with systemic lupus erythematosus. Nat Genet 40: 152–154.
11. Han S, Kim-Howard X, Deshmukh H, Kamatani Y, Viswanathan P, et al.
(2009) Evaluation of imputation-based association in and around the integrin-
alpha-M (ITGAM) gene and replication of robust association between a non-
synonymous functional variant within ITGAM and systemic lupus erythema-
tosus (SLE). Hum Mol Genet 18: 1171–1180.
12. Kim-Howard X, Maiti AK, Anaya JM, Bruner GR, Brown E, et al. (2009)
ITGAM coding variant (rs1143679) influences the risk of renal disease, discoid
rash, and immunologic manifestations in lupus patients with European ancestry.
Ann Rheum Dis 69: 1329–1332.
13. Fagerholm SC, Varis M, Stefanidakis M, Hilden TJ, Gahmberg CG (2006)
Alpha-Chain phosphorylation of the human leukocyte CD11b/CD18 (Mac-1)
integrin is pivotal for integrin activation to bind ICAMs and leukocyte
extravasation. Blood 108: 3379–3386.
14. Rhodes B, Vyse TJ (2008) The genetics of SLE: an update in the light of
genome-wide association studies. Rheumatology (Oxford) 47: 1603–1611.
15. Koskenmies S, Ja ¨rvinen TM, Onkamo P, Panelius J, Tuovinen U, et al. (2008)
Clinical and laboratory characteristics of Finnish lupus erythematosus patients
with cutaneous manifestations. Lupus 17: 337–347.
16. Lin JH, Dutz JP, Sontheimer RD, Werth VP (2007) Pathophysiology of
cutaneous lupus erythematosus. Clin Rev Allergy Immunol 33: 85–106.
17. Koskenmies S, Widen E, Kere J, Julkunen H (2001) Familial systemic lupus
erythematosus in Finland. J Rheumatol 28: 758–760.
18. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, et al. (1982) The 1982
revised criteria for the classification of systemic lupus erythematosus. Arthritis
Rheum 25: 1271–1277.
19. Popovic K, Nyberg F, Wahren-Herlenius M, Nyberg F (2007) A serology-based
approach combined with clinical examination of 125 Ro/SSA-positive patients
to define incidence and prevalence of subacute cutaneous lupus erythematosus.
Arthritis Rheum 56: 255–264.
20. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, et al.
(2002) Classification criteria for Sjogren’s syndrome: a revised version of the
European criteria proposed by the American-European Consensus Group. Ann
Rheum Dis 61: 554–558.
21. Mosca M, Neri R, Bombardieri S (1999) Undifferentiated connective tissue
diseases (UCTD): a review of the literature and a proposal for preliminary
classification criteria. Clin Exp Rheumatol 17: 615–620.
22. Tengner P, Halse AK, Haga HJ, Jonsson R, Wahren-Herlenius M (1998)
Detection of anti-Ro/SSA and anti-La/SSB autoantibody-producing cells in
salivary glands from patients with Sjogren’s syndrome. Arthritis Rheum 41:
2238–2248.
23. Stolt P, Bengtsson C, Nordmark B, Lindblad S, Lundberg I, et al. (2003)
Quantification of the influence of cigarette smoking on rheumatoid arthritis:
results from a population based case-control study, using incident cases. Ann
Rheum Dis 62: 835–841.
24. Jurinke C, van den Boom D, Cantor CR, Koster H (2002) Automated
genotyping using the DNA MassArray technology. Methods Mol Biol 187:
179–192.
25. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and
visualization of LD and haplotype maps. Bioinformatics 21: 263–265.
26. Yang W, Zhao M, Hirankarn N, Lau CS, Mok CC, et al. (2009) ITGAM is
associated with disease susceptibility and renal nephritis of systemic lupus
erythematosus in Hong Kong Chinese and Thai. Hum Mol Genet 18:
2063–2070.
27. Oke V, Vassilaki I, Espinosa A, Strandberg L, Kuchroo VK, et al. (2009) High
Ro52 Expression in Spontaneous and UV-Induced Cutaneous Inflammation.
J Invest Dermatol 129: 2000–2010.
28. Popovic K, Brauner S, Ek M, Wahren-Herlenius M, Nyberg F (2007) Fine
specificity of the Ro/SSA autoantibody response in relation to serological and
clinical findings in 96 patients with self-reported cutaneous symptoms induced by
the sun. Lupus 16: 10–17.
29. Popovic K, Wahren-Herlenius M, Nyberg F (2008) Clinical follow-up of 102
anti-Ro/SSA-positive patients with dermatological manifestations. Acta Derm
Venereol 88: 370–375.
30. Kuhn A, Sonntag M, Sunderkotter C, Lehmann P, Vestweber D, et al. (2002)
Upregulation of epidermal surface molecule expression in primary and
ultraviolet-induced lesions of lupus erythematosus tumidus. Br J Dermatol
146: 801–809.
31. Hammerberg C, Katiyar SK, Carroll MC, Cooper KD (1998) Activated
complement component 3 (C3) is required for ultraviolet induction of
immunosuppression and antigenic tolerance. J Exp Med 187: 1133–1138.
32. Kang K, Gilliam AC, Chen G, Tootell E, Cooper KD (1998) In human skin,
UVB initiates early induction of IL-10 over IL-12 preferentially in the expanding
dermal monocytic/macrophagic population. J Invest Dermatol 111: 31–38.
33. Kolgen W, Van Weelden H, Den Hengst S, Guikers KL, Kiekens RC, et al.
(1999) CD11b+ cells and ultraviolet-B-resistant CD1a+ cells in skin of patients
with polymorphous light eruption. J Invest Dermatol 113: 4–10.
34. Takahara M, Kang K, Liu L, Yoshida Y, McCormick TS, et al. (2003) iC3b
arrests monocytic cell differentiation into CD1c-expressing dendritic cell
precursors: a mechanism for transiently decreased dendritic cells in vivo after
human skin injury by ultraviolet B. J Invest Dermatol 120: 802–809.
35. Suarez A, Lopez P, Mozo L, Gutierrez C (2005) Differential effect of IL10 and
TNF{alpha} genotypes on determining susceptibility to discoid and systemic
lupus erythematosus. Ann Rheum Dis 64: 1605–1610.
36. Werth VP, Zhang W, Dortzbach K, Sullivan K (2000) Association of a promoter
polymorphism of tumor necrosis factor-alpha with subacute cutaneous lupus
erythematosus and distinct photoregulation of transcription. J Invest Dermatol
115: 726–730.
37. Montecucco F, Steffens S, Burger F, Da Costa A, Bianchi G, et al. (2008) Tumor
necrosis factor-alpha (TNF-alpha) induces integrin CD11b/CD18 (Mac-1) up-
regulation and migration to the CC chemokine CCL3 (MIP-1alpha) on human
neutrophils through defined signalling pathways. Cell Signal 20: 557–568.
38. Millard TP, Kondeatis E, Cox A, Wilson AG, Grabczynska SA, et al. (2001) A
candidate gene analysis of three related photosensitivity disorders: cutaneous
lupus erythematosus, polymorphic light eruption and actinic prurigo.
Br J Dermatol 145: 229–236.
39. Vera-Recabarren MA, Garcia-Carrasco M, Ramos-Casals M, Herrero C (2010)
Cutaneous lupus erythematosus: clinical and immunological study of 308
patients stratified by gender. Clin Exp Dermatol 35: 729–735.
40. Fairweather D, Frisancho-Kiss S, Rose NR (2008) Sex differences in
autoimmune disease from a pathological perspective. Am J Pathol 173: 600–609.
ITGAM in Cutaneous Lupus
PLoS ONE | www.plosone.org 8 December 2010 | Volume 5 | Issue 12 | e14212